Tivic Health Systems develops FDA‑cleared bioelectronic devices that use microcurrent waveforms to treat allergy‑related sinus pain without drugs. Its first consumer product, ClearUP Sinus Pain Relief, is clinically proven, available without a prescription and priced at $149. ClearUP delivers low‑level electrical stimulation to nerves under the cheek, nose and eyebrow bone. The company, founded in 2016 and led by CEO Jennifer Ernst, has raised capital in a series of tranches. Tivic recently closed the most recent tranche of an $8M seed financing and intends to use the proceeds for marketing of ClearUP. Backers include angel groups, a physician network and individual investors.

Total raised

$8M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2019